General discussion, page-10

I suspect this stock will sneak up on the market. Normally with medtechs like Microbia they are full of promise but there is a couple of years of pre-revenue clinical studies to get through. The reality is that for many of these companies you can buy their shares now or you can buy them in 18 months and still get them at a similar price. And Microbia would seem to be no different when it comes to its product pipeline but for the fact that it has a separate activity - selling microbiome tests to the public - which means it already has revenue flow and that flow is likely to increase substantially over the next 9 months or so. They might bomb in the meantime but there is a reasonable chance that the share price you will pay in 18 months will be quite different to the share price you can pay now ... but I may be totally wrong here.